




# Natera, Inc.

## Investor presentation

---

**Second Quarter 2022 Earnings Call**  
August 4, 2022



# Safe harbor statement



This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our proposed products and launch schedules, our reimbursement coverage and our product costs, our commercial partners and potential acquisitions, our user experience, our clinical trials and studies, our financial performance, our strategies, our anticipated revenue and financial outlook, our goals and general business and market conditions, are forward-looking statements.

These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including: we face numerous uncertainties and challenges in achieving our financial projections and goals; we may be unable to maintain our business and operations as planned due to disruptions and economic uncertainty caused by the COVID-19 pandemic; we may be unable to further increase the use and adoption of Panorama and Horizon through our direct sales efforts or through our laboratory partners; we may be unable to develop and successfully commercialize new products, including Signatera and Prospera; we have incurred losses since our inception and we anticipate that we will continue to incur losses for the foreseeable future; our quarterly results may fluctuate from period to period; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we may be unable to compete successfully with existing or future products or services offered by our competitors; we may engage in acquisitions, dispositions or other strategic transactions that may not achieve our anticipated benefits and could otherwise disrupt our business, cause dilution to our stockholders or reduce our financial resources; we may need to raise additional capital to support our business plans, which may not be available when necessary or on favorable terms; we may not be successful in commercializing our cloud-based distribution model; our products may not perform as expected; the results of our clinical studies, including our SNP-based Microdeletion and Aneuploidy RegisTry, or SMART, Study, may not be compelling to professional societies or payors as supporting the use of our tests, particularly in the average-risk pregnancy population or for microdeletions screening, or may not be able to be replicated in later studies required for regulatory approvals or clearances; if either of our primary CLIA-certified laboratory facilities becomes inoperable, we will be unable to perform our tests and our business will be harmed; we rely on a limited number of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials and may not be able to find replacements or immediately transition to alternative suppliers; if we are unable to successfully scale our operations, our business could suffer; the marketing, sale, and use of Panorama and our other products could result in substantial damages arising from product liability or professional liability claims that exceed our resources; we may be unable to expand, obtain or maintain third-party payer coverage and reimbursement for Panorama, Horizon and our other tests, and we may be required to refund reimbursements already received; third-party payers may withdraw coverage or provide lower levels of reimbursement due to changing policies, billing complexities or other factors, such as the increased focus by third-party payers on requiring that prior authorization be obtained prior to conducting a test; if the FDA were to begin actively regulating our tests, we could incur substantial costs and delays associated with trying to obtain premarket clearance or approval and incur costs associated with complying with post-market controls; litigation or other proceedings, resulting from either third party claims of intellectual property infringement or third party infringement of our technology, is costly, time-consuming and could limit our ability to commercialize our products or services; any inability to effectively protect our proprietary technology could harm our competitive position or our brand; and we cannot guarantee that we will be able to service and comply with our outstanding debt obligations or achieve our expectations regarding the conversion of our outstanding convertible notes. We discuss these and other risks and uncertainties in greater detail in the sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our periodic reports on Forms 10-K and 10-Q and in other filings we make with the SEC from time to time. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and our actual results could differ materially and adversely from those anticipated or implied. As a result, you should not place undue reliance on our forward-looking statements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations. We file reports, proxy statements, and other information with the SEC. Such reports, proxy statements, and other information concerning us is available at <http://www.sec.gov>. Requests for copies of such documents should be directed to our Investor Relations department at Natera, Inc., 13011 McCallen Pass, Building A Suite 100, Austin, TX 78753. Our telephone number is (650) 249-9090.



## Recent highlights


---

- Total revenues of \$198.2M; ~40% growth over Q2 21
- ~500K total tests processed in Q2 22; ~33% growth vs. Q2 21
- 2022 revenue guidance raised to \$805 million – \$825 million
- Selected to participate in UHC's Preferred Laboratory Network after a rigorous review process
- Publication of the Trifecta study for Prospera Kidney in *Transplantation*; largest prospective, multisite, fully biopsy matched study to date
- Completed enrollment in RenaCARE study for Renasight, with more than 1,700 patients at 30+ sites
- Secured Medicare coverage for muscle invasive bladder cancer; fourth coverage decision for Signatera
- Presented substantial new Signatera data sets at the 2022 ASCO Annual Meeting
- Appointed Dr. Minetta Liu as CMO for Oncology
- Additional equity investment in Natera by Executive Chairman Matt Rabinowitz

## Record Q2 22 volume of 500,000 units



- ~33% volume growth over Q2 21
- Strong market share gains in Women's Health
- Continued momentum in Organ Health and Oncology
- Overcame normal Q1 to Q2 sequential seasonality




## Revenues accelerating with volume growth



- ~40% revenue growth over Q2 21
- Steady NIPT ASP growth
- Strong sequential ASP growth in Oncology:
  - Medicare mix improving
  - Volume shift to recurrence monitoring

Total revenues: year on year trend  
(\$ in millions)



## Selected for United Healthcare's Preferred Lab Network




- Rigorous review process of contracted laboratory care providers who have met higher standards for access, cost, data, quality, and service
- Shared commitment toward driving affordability, outcomes, and patient experience
- One of only 12 participating labs in the U.S.
- More than 48 million members and 110,000 physicians in UNH network
- Effective July 1st, 2022




# Women's Health TAM: Average risk NIPT will help millions of patients per year



## ACOG/SMFM support



## ~4.4M pregnancies in U.S.<sup>1</sup>




1. CDC, National Vital Statistics Reports Volume 70, Number 2 March 23, 2021. Estimates based on number of pregnancies at week 5  
Not for reproduction or further distribution.

# Landmark SMART study published in AJOG



## SMART publication



## Key results

### Only 22q test validated in real-world, multi-site prospective study:

- Robust validation with confirmed outcomes in >18,000 patients

### 22q results exceeded expectations:

- High incidence 1/1,524, excellent sensitivity and specificity
- High PPV of 53% (>10X better than historically accepted screening tests)
- Detected more difficult, smaller 22q deletions (41% of cases)

### High clinical utility for 22q screening:

- One of the leading causes of congenital heart defects in the general population<sup>1</sup>
- Helps to avoid post-natal diagnostic odyssey – average of 4.7 years to diagnose
- Early interventions can improve outcomes

1. McDonald-McGinn DM, Sullivan KE, Marino B, et al. 22q11.2 deletion syndrome. Nat Rev Dis Primers. 2015;1:15071. Published 2015 Nov 19. doi:10.1038/nrdp.2015.71  
Not for reproduction or further distribution.



# Prospera Kidney – Trifecta Study published in Transplantation

Prospera™  
Transplant assessment



## Prospera Kidney with Quantification

Transplantation

### Trifecta Study

- Largest prospective, fully biopsy-matched, multi-site study of dd-cfDNA for kidney transplant recipients performed to date
- >300 biopsy-matched samples
  - Includes >100 biopsy-confirmed rejections
- 20+ US & international sites
- The combination of dd-cfDNA fraction and estimated quantity of dd-cfDNA demonstrated significantly improved performance compared to rejection assessment using donor fraction alone.

Source: Halloran PF, Reeve J, Madill-Thomsen KS, et al. Combining Donor-derived Cell-free DNA Fraction and Quantity to Detect Kidney Transplant Rejection Using Molecular Diagnoses and Histology as Confirmation [published online ahead of print, 2022 Jun 29]. Transplantation. 2022;10.1097/TP.0000000000004212. doi:10.1097/TP.0000000000004212  
Not for reproduction or further distribution.

# Renasight – completes enrollment in RenaCARE study

Renasight™  
Kidney gene panel



## U.S. Unmet Need in CKD

- 37 million patients with chronic kidney disease (CKD), with 750,000 patients newly diagnosed each year<sup>1</sup>
- 2019 NEJM study found ~10% of patients had a genetic basis for their CKD; similar diagnostic yield to cancer<sup>2</sup>
- For patients with a positive genetic finding, 89% of patients had clinical utility<sup>3</sup>



## RenaCARE

- Real-world, prospective, multi-center study to assess clinical utility of the Renasight genetic testing panel
- Enrollment completed in July – more than 1,700 patients across 30+ US sites
- Expected to submit study for publication in late 2022

1. Chronic Kidney Disease in the United States, 2021. [www.cdc.gov](https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html#:~:text=CKD%20is%20Common%20Among%20US%20Adults&text=More%20than%201%20in%207). Published March 9, 2021. <https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html#:~:text=CKD%20is%20Common%20Among%20US%20Adults&text=More%20than%201%20in%207>
2. Groopman EE, Marasa M, Cameron-Christie S, et al. Diagnostic Utility of Exome Sequencing for Kidney Disease. *N Engl J Med*. 2019; 380:142-151 DOI: 10.1056/NEJMoa1806891
3. Bleyer AJ, Westemeyer M, Xie J, et al. Genetic Etiologies for Chronic Kidney Disease Revealed through Next-Generation Renal Gene Panel. *Am J Nephrol*. 2022 Mar 24;1-10. doi: 10.1159/000522226.

Not for reproduction or further distribution.

# Signatera – Medicare coverage for Muscle Invasive Bladder Cancer

Signatera™  
Residual disease test (MRD)



## Local Coverage Determination (LCD)

### MoIDX: Minimal Residual Disease for Cancer

- Received written confirmation from CMS MoIDX for coverage of Signatera in muscle invasive bladder cancer effective April 19th, 2022
- Indications include neoadjuvant, adjuvant, and recurrence monitoring
- Reimbursement with established z-codes
- First coverage expansion under foundational LCD for MRD testing in solid tumors (LCD L38779), published in December 2021




### Medicare Local Coverage Determinations (LCDs) for Signatera

- **Early-stage colorectal cancer** – September 2020
- **Oligometastatic colorectal cancer (Stage IV)** – July 2021
- **Pan-cancer immunotherapy response monitoring** – November 2021
- **Muscle invasive bladder cancer** – July 2022

NEW

# MIBC estimated market size of ~400K MRD tests per year

**Signatera™**  
Residual disease test (MRD)



- Median age of dx = 73<sup>1</sup>
- Heavy Medicare mix with ~75% > age 65
- Anticipated testing schedule includes 10-12 tests per patient:
  - Y1: 4-6x
  - Y2: 2-4x
  - Y3: 1-2x
  - Y4: 1-2x
  - Y5: 1-2x

1. Cancer of the Urinary Bladder - Cancer Stat Facts. SEER. Published 2018. <https://seer.cancer.gov/statfacts/html/urinb.html>  
2. Source: Kantar Health (Cerner Enviza) estimate.  
Not for reproduction or further distribution.

# Signatera addresses major clinical challenges in MIBC

**Signatera™**  
Residual disease test (MRD)



## Neoadjuvant Chemo:

**Is the patient responding to treatment, can they proceed to radical cystectomy?**

- 60% patients don't respond to NAC<sup>2</sup>
- Lack of biomarkers to assess response, delaying potentially more effective therapy

## Adjuvant:

**Who has residual disease to potentially benefit from adjuvant therapy?**

- 50-65% of patients are cured after surgery, while 35-50% experience distant recurrence<sup>3,4</sup>
- Immunotherapy recently approved for adjuvant use (2021)

## Surveillance:

**How to identify recurrence prior to clinical symptoms?**

- Early detection of recurrence leads to better outcomes, but > 50% of relapses still detected too late<sup>5</sup>
- NCCN recommends intensive monitoring

1. TURBT = trans urethral resection of bladder tumor

2. Zargar H, et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. *European urology*. 2015;67(2):241-249.

3. Hautmann RE, et al. Radical Cystectomy for Urothelial Carcinoma of the Bladder Without Neoadjuvant or Adjuvant Therapy: Long-Term Results in 1100 Patients. *European Urology*. 2012/05/01/ 2012;61(5):1039-1047. <https://pubmed.ncbi.nlm.nih.gov/22381169>

4. Yun-Sok Ha, Tae-Hwan Kim (2018), Chapter 30 - The Surveillance for Muscle-Invasive Bladder Cancer (MIBC). In Ja Hyeon Ku (Ed.). *Bladder Cancer* (pp 553-597) Academic Press. doi.org/10.1016/B978-0-12-809939-1.00036-9

5. Boorjian SA, et al. Detection of asymptomatic recurrence during routine oncological follow up after radical cystectomy is associated with improved patient survival. *J Urol*. Nov 2011;186(5)


Not for reproduction or further distribution.

# Published evidence supports Signatera use in neoadjuvant, adjuvant and surveillance settings

**Signatera™**  
Residual disease test (MRD)




## Christensen et al, *Journal of Clinical Oncology* 2019<sup>1</sup>



**100% sensitivity to relapse with serial monitoring**  
**Average lead time 2.8 months**

## Powles et al, *Nature* 2021<sup>2</sup>



**Post-surgical MRD assessment is predictive of immunotherapy benefit**


1. Christensen E, Birkenkamp-Demtröder K, Sethi H, et al. Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients with Urothelial Bladder Carcinoma. *Journal of Clinical Oncology*. 2019; 37(18):1547-1557.

2. Powles T, Assaf ZJ, Davarpanah N, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. *Nature*. 2021;595:432-437.

Not for reproduction or further distribution.

## Pan-cancer platform positioned to scale

- One commercial team, one technology, many indications unlocked over time



Source: Internal estimates










Not for reproduction or further distribution.

# Signatera pan-cancer clinical pipeline

## Near term publications

Indication	Description	Patients	Plasma time points
CRC	CIRCULATE GALAXY with 18m followup	>1,000	>7,000
CRC	Multi center	>300	>1,300
Gastroesophageal	Multi center	>275	>900
Pancreatic	Multi center	>175	~500
Breast	EBLIS expanded cohort	>175	>1,200
Breast	ISPY 2.0 expanded cohort	>275	>1,000
Ovarian	Multi center	>50	>150
Melanoma	Single center	>50	>500


## Longer term prospective trials

	Phase III CIRCULATE Japan (CRC)		Phase III CIRCULATE US (CRC)		
	Phase III CDx study (MIBC)		Phase III CDx study (TNBC)		
	BESPOKE CRC (CRC)		BESPOKE IO (Pan-cancer)		
	AMPLIFY (Multi)		DARE (Breast)		LEADER (Breast)

Building evidence to change practice guidelines



# Signatera coverage roadmap



## Q2 financial overview



(\$ in millions, except for per share data)

P&L	Q2'22	Q2'21	Change
Product Revenues	\$194.6	\$139.6	\$55.0
Licensing and Other Revenues	\$3.6	\$2.4	\$1.2
Total Revenues	\$198.2	\$142.0	\$56.2
Gross Margin% <sup>1</sup>	44.9%	46.4%	(150 bps)
R&D	\$82.6	\$53.8	\$28.8
SG&A	\$149.5	\$127.5	\$22.0
Net Loss Per Diluted Share	(\$1.50)	(\$1.32)	(\$0.18)

Balance sheet	Jun 30, 2022	Mar 31, 2022	Change Q/Q
Cash & Investments <sup>2</sup>	\$638.7	\$752.2	(\$113.5)
UBS Line of Credit	\$50.1	\$50.1	\$ —
Convertible Senior Notes <sup>3</sup>	\$281.0	\$280.7	\$0.3

1. Gross margin is calculated as gross profit divided by GAAP total revenues. Gross profit is calculated as GAAP total revenues less GAAP cost of revenues.

2. Cash and investments also include cash equivalents and restricted cash.

3. This balance reflects net carrying value for the Convertible Senior Notes under ASC 470-20 while the gross principal amounts outstanding is \$287.5 million as of June 30, 2022.

Not for reproduction or further distribution.

# Well positioned for scale



## Natera Today

- Established products with clear market leadership position
- Addressing large unmet clinical needs
- Volumes, revenues continuing to ramp quickly
- Multi-year lead in published data in women's health, oncology
- Commercial teams fully built to support increased future adoption



## Near Future

- Multiple large potential catalysts:
  - Microdeletions guideline inclusion
  - Signatera colorectal cancer NCCN guideline inclusion
  - Signatera commercial payer coverage
  - MolDx coverage for additional tumor types
- R&D yielding COGS and scale benefits:
  - High volume products on lower-cost sequencers
  - Scaling tissue whole exome capability, lower-cost lab operations
- Stable operating expenses
  - Stable commercial presence
  - Stable investment in clinical trials

## Raising 2022 annual guidance



Guide \$ (millions)	Original	Q1 22	Q2 22	Key drivers
<b>Revenue</b>	\$770 - \$790	\$790 - \$810	<b>\$805 - \$825</b>	<ul style="list-style-type: none"> <li>• Volume outperformance</li> <li>• Increasing ASPs</li> </ul>
<b>Gross margin % revenue</b>	46% - 48%	46% - 48%	<b>46% - 48%</b>	<ul style="list-style-type: none"> <li>• Improving ASP trends</li> </ul>
<b>SG&amp;A</b>	\$560 - \$590	\$560 - \$590	<b>\$560 - \$590</b>	<ul style="list-style-type: none"> <li>• Commercial teams built out</li> </ul>
<b>R&amp;D</b>	\$340 - \$360	\$340 - \$360	<b>\$340 - \$360</b>	<ul style="list-style-type: none"> <li>• Foundational clinical trials and lab workflow expansion</li> </ul>
<b>Cash burn</b>	\$370 - \$400	\$370 - \$400	<b>\$370 - \$400</b>	<ul style="list-style-type: none"> <li>• Poised to decline in 2023 and beyond</li> </ul>

**Expecting quarterly cash flow breakeven in mid-2024**



Not for reproduction or further distribution.

